IRIS Metals Limited (ASX: IR1) has reported high-grade rubidium assay results from its 2023 and 2024 drilling programs at the Beecher Project, located in the southern Black Hills of South Dakota, USA (Figure 1). The results confirm a significant rubidium discovery alongside the project’s established lithium resource, further positioning Beecher as a multi-commodity critical minerals asset in a mining-friendly U.S. jurisdiction.

Viking Mines Limited (ASX: VKA) has announced the acquisition of a high-grade, production-proven tungsten portfolio in Nevada, USA, a Tier-1 mining jurisdiction (Figure 1). The transaction provides Viking with 100% exposure to six historical tungsten projects located in close proximity to strategic US defence infrastructure, positioning the Company within a critical minerals supply chain at a time of heightened geopolitical urgency.

IRIS Metals Limited (ASX: IR1) has secured an exclusive right to farm-in to the Finley Basin Tungsten Project, located in Granite County, Montana, USA, through a binding Heads of Agreement with Finley Mining Inc and its shareholders. The transaction provides IRIS with entry into a historically high-grade tungsten system within a mining-friendly U.S. jurisdiction, aligning with its broader critical minerals strategy and U.S.-focused asset base.

Pioneer Minerals Ltd (ASX: PMM) (formerly Pioneer Lithium Ltd) is advancing its North Pine Project in Idaho, USA, a region renowned for its Tier-1 critical minerals endowment (Figure 1). The latest field program has delivered multiple high-grade tungsten and gold results from the Springfield Prospect, alongside the identification of a new polymetallic precious-metal system at Silver Cliffs. These results materially expand the exploration proposition across the broader North P

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has presented important data from its ATH434-201 Phase 2 clinical trial at the 150th Annual Meeting of the American Neurological Association (ANA) in Baltimore, USA. The trial focused on Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. These results mark a significant milestone for Alterity as it moves closer to providing the first disease-modifying therapy for MSA.